The stock market is best navigated with insights from top analysts, offering authoritative, professional, timely, and comprehensive research to help you uncover potential opportunities.
On the morning of July 9, 2026, at the Shanghai Financial Court, a securities misrepresentation liability dispute case with docket number (2026) Hu 74 Min Chu No. 321 commenced on schedule. Ten investors sat on the plaintiff's side, while the defendant's bench listed three parties: Lanhai Medical, its actual controller Mi Chunlei, and CITIC Securities.
Here was a company that had been delisted for four years, essentially a shell, a "deadbeat debtor" restricted from high-consumption activities, alongside the undisputed leader in the brokerage industry. The appearance of these three parties on the same defendant's bench itself tells a story of immense tension.
At the center of this story is Mi Chunlei, who holds another identity more widely known to the public: the husband of CCTV host Dong Qing. Consequently, the narrative that "Dong Qing's husband caused huge losses for CITIC Securities" quickly became the most popular interpretation of this case.
The Root of the Trouble: A 583 Million Yuan Private Placement
Lanhai Medical's predecessor was Zhonghai Haisheng, a shipping company listed on the Shanghai Stock Exchange in 1996. Between 2015 and 2016, Mi Chunlei, through his "Lanhai" group of companies, spent approximately 3 billion yuan to gain control, securing a 42.82% stake and becoming the new actual controller. After taking over, he divested the original shipping assets, renamed the company Lanhai Medical, and claimed a full transition into high-end medical services.
However, this transformation never succeeded. From 2019 to 2021, Lanhai Medical's non-GAAP net profit showed losses of 191 million yuan, 166 million yuan, and 319 million yuan respectively. Hospital construction required continuous investment, while revenue persistently failed to cover costs, causing the listed platform to gradually lose its ability to generate funds internally.
In November 2020, Lanhai Medical completed a private placement, issuing approximately 156 million shares at 3.78 yuan per share, raising a total of 589 million yuan. After deducting issuance costs, the net proceeds amounted to about 583 million yuan. CITIC Securities acted as the exclusive sponsor and underwriter and continued to bear the responsibility for ongoing supervision after the issuance.
Misappropriation of 575 Million Yuan Leads to Delisting
Subsequently uncovered fund problems closely matched the amount of this private placement. According to a disciplinary decision by the Shanghai Stock Exchange, the Lanhai Group, through enterprises it controlled or could significantly influence, misappropriated a cumulative 575 million yuan from the listed company in 2021, accounting for 25.59% of Lanhai Medical's audited net assets at the end of 2020. Of this, 25 million yuan directly involved the raised funds.
By the end of 2021, approximately 109 million yuan in misappropriated funds remained unrepaid. In January 2022, a 441 million yuan loan previously provided by Lanhai Medical to the related party Shanghai Hefeng Hospital matured and was not recovered, which was also deemed to constitute non-operational fund misappropriation. This indicated the problem had escalated beyond a temporary diversion of a single fund.
In January 2022, Mi Chunlei authorized director Ni Xiaowei to perform the chairman's duties on his behalf and subsequently disappeared from public view for nearly six months.
In April 2022, Lanhai Medical's 2021 financial report received a qualified audit opinion, and its internal controls received an adverse opinion. Ultimately, the company triggered financial delisting criteria. On July 25, 2022, Lanhai Medical was delisted by the Shanghai Stock Exchange, ending its 26-year journey as an A-share listed company. Before delisting, its stock price fell to 1.12 yuan per share, a drop of over 90% from its historical high.
Approximately 30,000 investors lost their entire investment.
Why is CITIC Securities on the Defendant's Bench?
The direct reason for CITIC Securities being listed as a co-defendant is a continuous supervision report.
From February 24 to 25, 2022, two sponsor representatives from CITIC Securities, Dong Zhiru and Yang Qin, conducted an on-site inspection of Lanhai Medical. On March 4, CITIC Securities issued a report stating that the company's raised funds were all deposited in dedicated accounts and there were no violations in their use; as of the inspection date, there was also "no situation of related parties illegally occupying the listed company's funds."
However, the facts were precisely the opposite. In December 2022, the Shanghai Stock Exchange issued a public reprimand to the two sponsor representatives, determining that they "failed to discover and promptly disclose the company's violations and significant risk events regarding the management of raised fund usage and the occupation of funds by related parties."
Investors believe that CITIC Securities, as the sponsor, failed to fulfill its duty of diligence and care, and that its negligence has a causal relationship with the investment losses, thus it should bear joint and several liability for compensation.
Courtroom Debate: Who Harmed Whom?
During the July 9th trial, both sides presented their arguments.
Mi Chunlei admitted to the fact of fund misappropriation but argued that the losses caused by the delisting included market fluctuation factors and should not be borne by him alone.
CITIC Securities argued that Mi Chunlei deliberately concealed the flow of funds, making it impossible for the company to verify the situation at the corporate level.
The question remains: as the "gatekeeper" of the capital market receiving exorbitant sponsorship fees, what exactly were they watching?
The regulatory authorities' previous determination may offer part of the answer—the two sponsor representatives failed to be diligent and responsible, and the verification opinions they issued were inaccurate. Whether this administrative conclusion will further translate into civil compensation liability is the biggest suspense of this lawsuit.
The case has not yet been adjudicated.
The Fall of a Billionaire
Mi Chunlei was born in 1978 into a rural family on Chongming Island, Shanghai. Regarding the history of his fortune, two completely different versions circulate: one says he graduated from Tongji University and made his fortune in road construction; the other claims he made a fortune overnight through futures trading. In 2003, at just 25 years old, he boldly invested 40 million yuan, co-founding Shanghai Zhongying Enterprise Development Co., Ltd. with his father Mi Boyuan with a total capital of 50 million yuan—the predecessor of the Lanhai Group.
Thereafter, Mi Chunlei's capital empire expanded rapidly, extending its reach into insurance, banking, real estate, healthcare, automobiles, and cultural tourism. On the 2020 and 2021 Hurun Rich Lists, he was listed with a net worth of 10.5 billion yuan.
Today, Mi Chunlei has cumulative enforcement amounts against him of approximately 933 million yuan, has been restricted from high consumption 17 times, and all his equity and property holdings have been frozen. He cannot fly or even take second-class seats on high-speed trains.
Four years after Lanhai Medical's delisting, investor rights protection continues. According to Tianyancha information, there are currently 9 court records for securities misrepresentation cases involving Lanhai Medical, with 4 related lawsuits filed within the past year alone.
The direction of this lawsuit not only concerns the vital interests of the 10 investors but also relates to a larger question: when a listed company commits fraud, explodes, and delists, what responsibility should the sponsoring institution, as the "gatekeeper," bear?
Comments